Abstract
This article highlights a unique time in the history of Hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure Hepatitis C is discussed.
Original language | English (US) |
---|---|
Pages (from-to) | 129-139 |
Number of pages | 11 |
Journal | Clinics in Liver Disease |
Volume | 17 |
Issue number | 1 |
DOIs | |
State | Published - Feb 1 2013 |
Externally published | Yes |
Keywords
- Alisporivir
- Cyclophilin
- Cyclophilin inhibitors
- Debio 025
- Interferon-free
- NIM 811
- Non-interferon
- SCY-635
ASJC Scopus subject areas
- Hepatology